Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai to File Lenvatinib for Approval in Japan, US, Europe as Early as June
February 6, 2014
- NDA for Lorcaserin Expected to Be Filed in Japan in FY2016 or Later: Eisai
February 5, 2014
- 396 Eisai Workers Take Voluntary Retirement, FY2013 Net Profit Forecast Revised Downward
February 5, 2014
- DSP Expands Collaboration with Edison for Development of Mitochondrial Disease Treatment
February 5, 2014
- Kyowa Kirin to Integrate Research and Development Divisions
February 4, 2014
- Drug Wholesalers Laud Medical Fee Cuts to Fix Lengthy Haggling, Pharmacy Chains Vexed by Rule
February 4, 2014
- Kyowa Kirin Drug Prices Expected to Slip by 7% Due to NHI Price Revision
February 4, 2014
- Asahi Kasei Pharma to Discontinue Development of Teribone Transdermal Patch Formulation in Japan
February 4, 2014
- Impact of FDA’s Ranbaxy Ban on Daiichi Sankyo Earnings “Unavoidable”: Mr Sakai
February 3, 2014
- Daiichi Sankyo to Shift to IFRS Starting from FY2013
February 3, 2014
- CSL Behring Launches Hizentra, 1st SC Immunoglobulin Therapy in Japan
February 3, 2014
- Teijin Picks Another Pharma Maven for President
February 3, 2014
- Chugai President Mum on Kadcyla Launch Timing, Price Talks with Regulators Still Ongoing
February 3, 2014
- Chugai Sales Climb 9.6%, Actemra Sales Exceed 100 Billion Yen
February 3, 2014
- Sanofi Demands Payment of $416 Million from Novartis over Dissolved Equa Deal
January 31, 2014
- Novartis Suspected of Drafting Conference Presentation Materials on “Sign” Trial
January 31, 2014
- Novartis Global Net Profit Falls 1%, Japan Sales Drop 15.8%
January 31, 2014
- Maruho to Acquire Distribution Rights for Atopic Dermatitis Drug Protopic from Astellas
January 31, 2014
- Sawai, Nichi-Iko Boosting Annual Production Capacity to 10 Billion Tablets Each in Anticipation of Future Market Growth
January 31, 2014
- Novartis Suspected of Drafting Letter of Consent for “Sign” Trial
January 30, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…